5-氯-1-(4-甲酰基苯氧基)甲基-2-(1H)-嘧啶酮 | 100944-95-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 5-氯-1-(4-甲酰基苯氧基)甲基-2-(1H)-嘧啶酮
• 英文名称: 5-chloro-1-(4-formylphenoxy)methyl-2(1H)-pyrimidinone
• 英文别名: 4-[(5-Chloro-2-oxopyrimidin-1-yl)methoxy]benzaldehyde
• CAS: 100944-95-4
• 化学式: C₁₂H₉ClN₂O₃
• 分子量: 264.668
• InChiKey: UWXFKBYSLUUPMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  59
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-氯-1-(4-甲酰基苯氧基)甲基-2-(1H)-嘧啶酮 在 sodium hydrogensulfite 作用下， 以 水 为溶剂， 以49%的产率得到5-氯-1-(4-甲酰基苯氧基)甲基-2-氧代-1,2,3,4-四氢嘧啶-4-磺酸钠
  参考文献：
  名称：

  Benneche, Tore; Strande, Per; Undheim, Kjell, Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1987, vol. 41, p. 448 - 454

  摘要：

  DOI：
• 作为产物：
  描述：

  4-羟基苯甲醛钠盐 在 磺酰氯 、 三乙胺 、 sodium iodide 作用下， 以 乙二醇二甲醚 、 二氯甲烷 为溶剂， 反应 24.0h， 生成 5-氯-1-(4-甲酰基苯氧基)甲基-2-(1H)-嘧啶酮
  参考文献：
  名称：

  Benneche, Tore; Strande, Per; Undheim, Kjell, Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1987, vol. 41, p. 448 - 454

  摘要：

  DOI：

文献信息

• Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
  申请人：Pulici Maurizio

  公开号：US20050020583A1

  公开（公告）日：2005-01-27

  Compounds which are amino-phthalazinone derivatives according to formula 1 and pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them are disclosed; these compounds or compostions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, autoimmune diseases and neurodegenerative disorders.

  公开了按照式1的氨基-菲嗪酮衍生物和其药学上可接受的盐，以及包含它们的制药组合物；这些化合物或组合物在治疗由于和/或与改变的蛋白激酶活性有关的疾病中是有用的，如癌症，细胞增殖性疾病，阿尔茨海默病，病毒感染，自身免疫性疾病和神经退行性疾病。
• Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
  申请人：Vanotti Ermes

  公开号：US20060264493A1

  公开（公告）日：2006-11-23

  The present invention provides a method for treating diseases caused by and/or associated with an altered protein kinase activity which comprises administering to a mammal in need thereof an effective amount of a tetracyclic pyrazole. The invention also provides specific tetracyclic pyrazole derivatives, useful intermediates, a library comprising at least two of them, a process for their preparation and the pharmaceutical compositions containing them, which are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, viral infections, autoimmune diseases and neurodegenerative disorders.

  本发明提供了一种治疗由改变的蛋白激酶活性引起和/或相关的疾病的方法，包括向需要治疗的哺乳动物中给予有效量的四环吡唑。本发明还提供了特定的四环吡唑衍生物、有用的中间体、包含至少两个四环吡唑衍生物的库、它们的制备方法以及含有它们的药物组合物，这些组合物对于治疗由改变的蛋白激酶活性引起和/或相关的疾病，如癌症、细胞增殖性疾病、病毒感染、自身免疫性疾病和神经退行性疾病非常有用。
• Pyrimidinone derivatives
  申请人：NYCOMED AS

  公开号：EP0160573A2

  公开（公告）日：1985-11-06

  Bisulphite adducts of compounds of formula (wherein R represents a group R2-CH-X-(CR4R5)nR3; R' represents a halogen atom or a trifluoromethyl group; R2 represents a hydrogen atom or a C1-4 alkyl, C1-4 alkanoyl or phenyl group; X represents an oxygen or a sulphur atom or a group , where R6 represents a formyl, C1-4 alkanoyl or C1-4 alkoxycarbonyl group; R3 represents a C6-10 carbocyclic aromatic group or a heterocyclic group containing a 5- or 6- membered unsaturated heterocyclic ring which ring contains one or more heteroatoms selected from 0, N and S and optionally carries a fused carbocyclic ring, which carbocyclic or heterocyclic group may carry one or more substituents selected from halogen atoms, C1-4 alkyl, C1-4 alkanoyl, C1-4 alkoxy, C1-4 alkoxycarbonyl, C1-4 alkylthio, hydroxyl, nitro, cyano and formyl groups, -NR7R8 groups (where R is a hydrogen atom or a C1-4 alkyl group, and RB is a hydrogen atom or a C1-4 alkyl, C1-4 alkanoyl or aroyl group) and C1-4 alkyl groups substituted by one or more hydroxy or -NR7R8 groups and halogen atoms; n is an integer having the value 0 or 1; and R4 and R5, which may be the same or different, each is a hydrogen atom or a C1-6 alkyl group) and salts of such adducts have metaphase arrest abilities and desirably good water solubilities and may be useful in combatting abnormal cell proliferation.

  式化合物的亚硫酸氢盐加合物 (其中 R 代表基团 R2-CH-X-(CR4R5)nR3； R' 代表卤素原子或三氟甲基； R2 代表氢原子或 C1-4 烷基、C1-4 烷酰基或苯基； X 代表氧原子、硫原子或基团。 其中 R6 代表甲酰基、C1-4 烷酰基或 C1-4 烷氧羰基； R3 代表 C6-10 碳环芳香基团或含有 5 或 6 成员不饱和杂环的杂环基团，该环含有一个或多个选自 0、N 和 S 的杂原子，并可选择带有一个融合碳环，该碳环或杂环基团可带有一个或多个选自卤素原子的取代基、C1-4烷基、C1-4烷酰基、C1-4烷氧基、C1-4烷氧羰基、C1-4烷硫基、羟基、硝基、氰基和甲酰基、-NR7R8基团（其中R为氢原子或C1-4烷基，RB为氢原子或C1-4烷基、C1-4烷酰基或甲酰基）以及被一个或多个羟基或-NR7R8基团和卤素原子取代的C1-4烷基； n 是数值为 0 或 1 的整数；以及 R4和R5，它们可以相同或不同，各自为氢原子或C1-6烷基）和这类加合物的盐具有移相抑制能力和理想的良好水溶性，可用于抑制异常细胞增殖。
• Sodium 2-Mercaptoethanesulfonate in Reversible Adduct Formation and Water Solubilization.
  作者：Frode Rise、Kjell Undheim、Peder Kierkegaard、Janina Legendziewicz、Ewa Huskowska、Lija Tekenbergs-Hjelte、Kristina Ohlson、Tomas Alminger、Magnus Erickson、Inger Grundevik、Inger Hagin、Kurt-Jürgen Hoffman、Svante Johansson、Sam Larsson、Ingalil Löfberg、Kristina Ohlson、Björn Persson、Inger Skånberg、Lija Tekenbergs-Hjelte

  DOI：10.3891/acta.chem.scand.43-0489

  日期：——

  Sodium 2-mercaptoethanesulfonate (MESNA, coenzyme M) forms 1:1 covalent adducts with highly pi-electron deficient heterocycles. The addition is caused by the thiol function, and the adducts become water soluble as sulfonates. 1H NMR spectroscopy has been used to obtain information about electronic and steric effects on the equilibria between 2-pyrimidinones and their 1:1 MESNA adducts. The adducts are potential prodrugs for biologically interesting 2-pyrimidinones.
• RISE, FRODE;UNDHEIM, KJELL, ACTA CHEM. SCAND., 43,(1989) N, C. 489-492
  作者：RISE, FRODE、UNDHEIM, KJELL

  DOI：——

  日期：——